About Legend Biotechnology
Legend Biotechnology is a publicly listed company based in Nanjing (China) founded in 2014 by Frank Fan. Cell therapies for cancer and infectious diseases are developed. Legend Biotechnology has raised $150.45 million across 2 funding rounds from investors including RA Capital, Hudson Bay Capital and Johnson & Johnson Innovation. The company has 2,610 employees. Its chief executive, as recorded, is Yuan Xu. Its website legendbiotech.com draws about 38 thousand monthly visits. Legend Biotechnology offers products and services including CARVYKTI. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell.
Company details
Legend Biotechnology was founded in 2014 in Nanjing, China, within the biotechnology sector. CAR-T cell therapies are developed by the company for hematologic malignancies, solid tumors, and infectious diseases. Operations center on advancing treatments through cellular immunotherapy. The focus remains on research and development to address unmet medical needs in oncology and infectious disease management. Leadership includes co-founder Frank Fan and CEO Yuan Xu.
- Headquarters Nanjing, China
- Employees 2,610
- Founders Frank Fan
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website legendbiotech.com
- Social LinkedIn X
- Legal Name Legend Biotech Corp. Sponsored Adr
- Annual Revenue$1.03 B (USD)64.39as on Dec 31, 2025
- Net Profit-$297.58 M (USD)-68.02as on Dec 31, 2025
- EBITDA-$107.88 M (USD)62.32as on Dec 31, 2025
- Total Equity Funding$150.45M (USD)
in 2 rounds
- Latest Funding Round$200M (USD), Post-IPO
Apr 2023
- InvestorsRA Capital
& 3 more
- Employee Count2,610
Products & Services of Legend Biotechnology
Legend Biotechnology offers a comprehensive portfolio of products and services, including CARVYKTI.
Therapy for treating relapsed or refractory multiple myeloma
Funding Insights of Legend Biotechnology
Legend Biotechnology has successfully raised a total of $150.45M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $150.45M
- Total Rounds 2
- Last Round Post-IPO — $200M
- First Round $150.45M
(Mar 2020)
- Investors Count 4
All 2 funding rounds of Legend Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | $200M | Post-IPO | – | – | – |
| Mar 2020 | $150.45M | Series D | – | Hudson Bay Capital, RA Capital Management | – |
4 investors in total: 4 institutional.
Investors in Legend Biotechnology
Legend Biotechnology has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include RA Capital, Hudson Bay Capital and Johnson & Johnson Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manages diversified investment funds and portfolios professionally. | 1997 | hudsonbaycapital.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
| jnjinnovation.com | ||||
| lillyasiaventures.com |
Investor details for Legend Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Legend Biotechnology
169 people are tracked at Legend Biotechnology (63 in leadership, 12 in board & advisors, 94 in team); the tracked headcount is 2,610.
| Name | Role | Group |
|---|---|---|
Frank Fan | Co-Founder | Leadership |
Yuan Xu | CEO | Leadership |
Catherine Cheng | Chief Of Staff To R&d President | Leadership |
Wendy Luo | Sr. Director, Head Of Preclinical Toxicology | Leadership |
Lauren Russell | Technical Lead, Associate Director | Leadership |
Frederik Buysse | General Manager | Leadership |
Carlos Santos | Chief Financial Officer | Leadership |
Mitena P | Talent Acquisition Partner | Leadership |
Tom Brieva | Vp, Head Of Technical Development | Leadership |
Faris Khan | Associate Director, Engineering | Leadership |
Beth Defino Hamilton | Executive Director Of US And Global Marketing, Carvykti Brand Head | Leadership |
Jerry Z Zhou | Associate Director Of Coporate Finance | Leadership |
Parker Munson | Director Of Finance | Leadership |
Alan Bash | President of CARVYKTI | Leadership |
Ying Huang | CEO | Leadership |
Ruth Antoine | Head Of Clinical Operations & Data Analytics Strategy | Leadership |
Guowei Fang | President of Research & Development | Leadership |
Jessie Yeung | Head Of Investor Relations And Public Relations | Leadership |
Mythili Koneru | Chief Medical Officer | Leadership |
Elaine Qian | VP, Global Head of Human Resources | Leadership |
149 more people are available in the full profile.
Complete people profiles for Legend Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Legend Biotechnology
Legend Biotechnology is a publicly listed company on the NASDAQ with ticker symbol LEGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Jun 2020
- Listed onNASDAQ: LEGN
- Listed entityLegend Biotech Corp. Sponsored ADR
- Exchange sectorHealth technology
- ISINUS52490G1022
- Share price$17.88 (+0.45% on the day) · 2026-10-13
- Market capitalisation$3.46B
- EPS (diluted, trailing year)$-0.51
- Volume (last session)2,458,993
Financials of Legend Biotechnology
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.03B | -$297.6M | -$107.9M |
| 2024 | $627.6M | -$177.1M | -$286.4M |
| 2023 | $284.9M | -$517.8M | -$421.4M |
| 2022 | $116.9M | -$445.8M | -$439.1M |
| 2021 | $68.9M | -$404.1M | -$380.6M |
Detailed financial statements for Legend Biotechnology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Legend Biotechnology
4 dated milestones of Legend Biotechnology across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Legend Biotechnology is founded.
- Funding First funding round of $150.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $200.0M.
Web traffic of Legend Biotechnology
The website of Legend Biotechnology (legendbiotech.com) receives about 38.1K visits a month and ranks #1,021,456 among all websites worldwide, #1,255 in Biotechnology and Pharmaceuticals.
- Monthly visits38.1K
▲ 41.3% vs previous month
- Unique visitors12.8K
per month
- Global rank#1,021,456
among all websites
- Category rank#1,255
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit2.1
- Average visit1 min 15 sec
- DevicesDesktop 62% · Mobile 38%
Websites whose visitors overlap most with Legend Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellectis.com | 100% | 10.1K | #2,255,178 | View details | |
| kyowakirin.com | 97% | 55K | #722,482 | View details | |
| ptcbio.com | 88% | 24.4K | #1,154,739 | View details | |
| aptose.com | 88% | 3.6K | #6,596,362 | View details | |
| biocentury.com | 88% | 85.7K | #514,907 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Legend Biotechnology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Legend Biotechnology
Complete news archive for Legend Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Legend Biotechnology
Legend Biotechnology was founded in 2014 and raised its 1st funding round 6 years after it was founded.
Legend Biotechnology is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
Yuan Xu is the CEO of Legend Biotechnology, as recorded in our data.
Legend Biotechnology is a funded company, having raised a total of $150.45M across 2 funding rounds to date. The company's 1st funding round was a Series D of $150.45M, raised on Mar 2020.
Legend Biotechnology has 2,610 employees.
Annual revenue of Legend Biotechnology is $1.03B as on Dec 31, 2025.
Legend Biotechnology was founded in 2014 in Nanjing, China, within the biotechnology sector. CAR-T cell therapies are developed by the company for hematologic malignancies, solid tumors, and infectious diseases. Operations center on advancing treatments through cellular immunotherapy. The focus remains on research and development to address unmet medical needs in oncology and infectious disease management. Leadership includes co-founder Frank Fan and CEO Yuan Xu.
Legend Biotechnology offers CARVYKTI.
Yes, Legend Biotechnology is publicly traded on NASDAQ under the ticker symbol LEGN.
Legend Biotechnology has 4 investors. Key investors include RA Capital, Hudson Bay Capital, Johnson & Johnson Innovation, and Lilly Asia Ventures.